MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 09:11:12 2024-06-27 EDT | ||
| 25.65 EUR / 25.96 EUR | +0.88% |
|
| Current month | +7.98% | ||
| 1 month | +7.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 25.65 | +0.27% |
| 24-06-26 | 25.58 | +0.59% |
| 24-06-25 | 25.43 | -0.63% |
| 24-06-24 | 25.59 | +1.75% |
| 24-06-21 | 25.15 | -0.67% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 08:53 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB4DK0 |
| ISIN | DE000MB4DK07 |
| Date issued | 2023-03-14 |
| Strike | 201 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 10.33 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.43 € |
|---|---|
| Lowest since issue | 10.69 € |
| Spread | 0.31 € |
| Spread % | 1.19% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
